Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Preos “Approvable” Pending Additional Clinical Data, NPS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA concerns regarding hypercalcemia and Preos’ injection device call for additional safety information for the osteoporosis therapy.

You may also be interested in...



AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million

NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.

AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million

NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.

NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide

Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel